Navigation Links
Bradmer announces 2009 first quarter operational and financial results
Date:5/7/2009

TSX: BMR

TORONTO, May 7 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") today announced its 2009 first quarter operational and financial results.

Operational Highlights

During the three months ended March 31, 2009, the Company commenced a strategic review of its operations, as more particularly described in news releases of the Company dated February 17, 2009, March 5, 2009, and March 31, 2009. Pursuant to the strategic review, the Company has closed its Phase III GLASS-ART Trial to further patient enrollment, as the completion of initial milestones was projected to fully exhaust the Company's cash resources, while capital market conditions restricted the ability to raise further capital at this time. Subsequent to March 31, 2009, the Company has executed on a cash conservation plan with a reduction of staff and clinical trial related expenses, while continuing to evaluate strategic options.

"Despite our pride in the progress made bringing Neuradiab from a single-site Phase II program to a multicenter Phase III registration trial, this is a time of considerable challenge for our sector," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "We continue our strategic evaluation of the future of the Company and ways in which we can achieve our objectives while being extremely attentive to the care of our patients and optimizing downside protection for our shareholders. The Board and Management look forward to sharing this plan with our stakeholders in the immediate near future. Our conservation of capital is evident in our reduced burn in Q1 2009 and will be the central theme of our emerging strategy."

Financial Results

Amounts in US dollars, unless specified otherwise, and results expressed in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

For the three months ended M
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer Medical Isotope Supply For Phase III Trial Secure
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
10. Bradmer announces new additions to management team
11. Bradmer announces 2008 first quarter operational and financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced ... donation drive that benefits the animal shelter and rescue communities. ... with the Humane Society of the United States’ Animal Shelter ... , As part of their participation, Park Cities Pet Sitter ... the Presents 4 Pets drive from their client base, as ...
(Date:8/20/2014)... PITTSBURGH, Aug. 20, 2014 A common approach to ... blood did not improve survival chances for people who ... experts at the University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number ... fastest growing companies. The Inc. 500 ranks Connexion Point 12th, ... Point is the #1 fastest growing company in Utah. , ... and its clients include four of the top 10 health ... and has offices and contact centers in Salt Lake City, ...
(Date:8/20/2014)... cancer - using Botox. A study presented in the ... shows that cancer growth could be suppressed by eliminating ... cancer stem cells. The approach thus treated the cancer. ... and efficient. The researchers have thus far tested the ... humans. , The nervous system is crucial in regulating ...
(Date:8/20/2014)... most common cause of endophthalmitis, a potentially blinding condition ... eye injections, are the well-known staphylococci ("staph") ... a study published in the August issue of ... years of cases at New York Eye and Ear ... study found that gram-positive bacteria, which include staph and ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Treating gastric cancer -- with Botox 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3
... Pills Can Make Headaches Worse, YONKERS, N.Y., ... from frequent headaches to talk to their doctors,before ... prescription,and over-the-counter pain medications can make headaches worse, ... who reports in,CR,s October issue on how some ...
... Resources and Helpline Now,Available, HARRISBURG, Pa., Sept. 2 ... Indoor Air Act fast approaching, the,Department of Health is ... the law that will ban smoking in most public ... Guidance and a downloadable toolkit for public places ...
... new presidential,administration on the way, health care reform ... on what may come, attendees of the 2008,Republican ... than,Halleland Health Consulting, which is making itself available ... group and its law firm parent -- Minneapolis-based,Halleland ...
... Inc.,(NYSE: CSA ) announces the signing of ... office building and outpatient treatment center in,Pensacola, Florida., ... first synergy project since the,closing of the merger ... Spencer Company). The project will include design/build,(architectural, engineering ...
... Californians took benefit of nation,s 1st such law, passed in ... with chronically ill kids have made use of California,s pioneering ... even aware it exists, according to researchers at the Rand ... family leave law. It is funded by employees through an ...
... Pollution, HARRISBURG, Pa., Sept. 2 The ... partnerships have,forecast an air quality action day for ... air quality forecast predicts Wednesday will be code ... Washington and,Westmoreland counties., The U.S. Environmental Protection ...
Cached Medicine News:Health News:Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs 2Health News:Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs 3Health News:PA Department of Health Reminds Businesses to Prepare to Implement Clean Indoor Air Act 2Health News:INTERVIEW AVAILABILITY: Halleland Health Consulting Makes Health Policy Expertise Available During RNC Week 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 3Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:Air Quality Action Day Forecast Wednesday for Pittsburgh Region 2
(Date:8/20/2014)... Trovagene, Inc. (NASDAQ:   TROV), a developer ... two clinical studies will be presented at the 29th ... test for the detection of high risk strains of ... take place in Seattle from ... a new U.S. patent was issued earlier this year ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive Devices ... medical device company, announced today that Mitsubishi Corporation has ... robotic visualization system in Japan . ... in Japan in the second ... the exclusive distributor for Karl Storz GMBH & Co. ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2